Quality of life dynamics in patients with knee osteoarthritis on intra-articular therapy with bioactive concentrate of small sea fish and domestically produced sodium hyaluronate

Abstract

Introduction. The quality of life in patients with osteoarthritis (OA) depends on the severity of functional disorders, pain syndrome and the efficacy of their pharmacological correction.Purpose of the study. To evaluate the dynamics of the life quality in patients with knee osteoarthritis treated with intra-articular injections of domestically produced sodium hyaluronate (synovial fluid prosthesis) or with bioactive concentrate of small sea fish (BACSSF).Materials and methods. 180 patients with knee osteoarthritis were examined. The study group consisted of 50 patients who received injections of sodium hyaluronate (prosthesis synovial fluid), intra-articularly. Comparison group included 30 patients treated with BACSSF 2 ml No. 5 intraarticularly. Control group consisted of 100 patients who received BACSSF intramuscularly 1 ml No. 20. Study design: duration 12 months with prospective monitoring of quality of life according to the SF-36 scale, six visits.Results. When included in the study, the level of physical and mental health components between the groups of patients differed statistically insignificantly (p = 0.369 and p = 0.089). According to the study results, used pharmacotherapy improved quality of life in all groups. However, the groups differed statistically significantly in the speed of achieving an analgesic effect, the severity of pain reduction and the duration of maintenance of the therapy effect. The best dynamics of the physical and mental components of health was in a group of patients with knee osteoarthritis treated with intra-articular sodium hyaluronate.Conclusions. In real clinical practice, it is not always possible to improve the quality of life of patients with knee osteoarthritis. Symptomatic delayed-release medications (SYSADOA) are effective in the early stages of the disease. The positive clinical effect of intra-articular therapy with sodium hyaluronate develops earlier and lasts longer than therapy with another SYSADOA (BACSSF).